Skip to content
Buy This GLP
← ToolsWhat the trials found

Expected Weight Loss

STEP 1 reported an average weight change of −14.9% in the semaglutide group. SURMOUNT-1 reported −20.9% in its highest-dose tirzepatide group. Our guide to GLP-1 weight-loss research explains who took part in the trials. The tool shows the share who reached each weight-loss threshold.

By Buy This GLP Editorial TeamDistributions read from the published trial reports

The arm mean, which is the figure you have already seen

33 lb — 14.9% of 220 lb over 68 weeks, ending near 187 lb. The placebo arm of the same trial averaged 5 lb, and both arms received lifestyle support.

How many participants reached each threshold

Each row shows the share in the selected treatment group who reached a weight-loss threshold reported by STEP 1. The percentages use participants with weight measurements at week 68.

Semaglutide 2.4 mg once weekly: share of participants reaching each weight-loss threshold in STEP 1
ThresholdAt your weightReached itDid not
5% or more11 lb86.4%placebo 31.5%13.6%
10% or more22 lb69.1%placebo 12%30.9%
15% or more33 lb50.5%placebo 4.9%49.5%

STEP 1 reported 5% and 10% and 15% thresholds. The two trials did not publish the same rungs, so the rows differ between molecules. Missing rungs are absent from the papers rather than from this page. Source: STEP 1, PMID 33567185.

What these trial results can tell you

The trial enrolled 1,961 adults with a body-mass index of 30 or higher, or 27 with a weight-related condition, and no diabetes and reported these outcomes at week 68. A group result cannot predict which threshold an individual will reach.

Once you know the monthly charge, the GLP-1 cost calculator can estimate what you would pay over the full plan term. Convert four-week charges to a calendar-month amount first and include mandatory fees.

How to read the trial results

Among STEP 1 participants with measurements at week 68, 50.5% of the semaglutide group lost at least 15% of their starting weight and 69.1% lost at least 10%. In SURMOUNT-1, an estimated 56.7% of the highest-dose tirzepatide group lost at least 20% by week 72. Those 72 weeks included dose escalation.

A threshold shows how outcomes varied within a group. The starting-weight input converts each threshold into pounds or kilograms. The percentages describe trial groups, and your starting weight does not change them.

One more gap between the trial and the purchase: both trials studied the medications under supervised trial conditions. Compounded preparations are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before marketing. The figures above describe semaglutide and tirzepatide as studied, not as sold.